STOCK MARKET BSE NSE

Glenmark launches new diabetes medicine

Glenmark Pharmaceuticals, a research-led global integrated pharmaceutical company, announced the launch of its new diabetes medicine ‘Remogliflozin’ in Kerala.

Published: 21st May 2019 06:49 AM  |   Last Updated: 21st May 2019 06:49 AM   |  A+A-

Diabetes

For representational purposes

By Express News Service

KOCHI: Glenmark Pharmaceuticals, a research-led global integrated pharmaceutical company, announced the launch of its new diabetes medicine ‘Remogliflozin’ in Kerala. The drug is meant for the treatment of type-2 diabetes mellitus (T2DM) in adults. The launch took place at The Gateway Hotel, Kochi on Monday. 

Being developed by a Japanese firm, India is the first country where remogliflozin is being launched. The tablets will be available as Remo and Remozen in India. 

The launch is happening in India because it is known as the diabetic capital of the world. Remogliflozin has been studied in 26 clinical trials globally, covering around 2,500 patients from various ethnicity. This drug is has been introduced with the aim of making medicine affordable to more people.

“Many are deprived of diabetes drug because of the high economic burden. This is where Remogliflozin is introduced. This can be afforded at Rs 25 per day,” said Alok Malik, senior VP of Glenmark. “The drug also provides cardio-protective benefits by way of reducing weight and blood pressure,” he said.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp